Description:

ODM derived from http://clinicaltrials.gov/show/NCT00185393

Link:

http://clinicaltrials.gov/show/NCT00185393

Keywords:
Versions (2) ▾
  1. 12/9/11
  2. 6/4/17
Uploaded on:

June 4, 2017

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
18 Years and older
Non Hodgkin Lymphoma stage III or IV at timepoint of diagnosis
Patients who have achieved a remission after first line chemotherapy
No less than 6 weeks and no more than 12 weeks since last dose of chemotherapy
written informed consent
Exclusion Criteria
Any other anticancer treatment for NHL except the preceding first line chemotherapy
Prior radiation therapy
Patients who have not recovered from the toxic effects of the first line chemotherapy
Any other cancer or history of cancer less than 10 years ago
Patients with known HIV positivity
patients with pleural effusion or ascites
female patients who are pregnant or breast feeding (women of childbearing potential must have a negative serum pregnancy test at study entry)
Adults not employing an effective method of birth control during study treatment and 12 months thereafter
Patients unable or unwilling to comply with protocol